Jason Aryeh
Director at Ligand Pharmaceuticals; Director at Orchestra BioMed Holdings; Director at Lifecore Biomedical. Based in Palm Beach Gardens, Florida.
- Rank
- 3493rd of 14,644
- Companies held
- 3
- Largest holding
- LGND, 96.1% of total
- Latest SEC filing
- Nov 10, 2026
- Listed but not counted
- $6.0M
What the $33.0M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND Common Stock | Directly | 105,476 | $286.94 | $30.3M | 91.8% | Form 4, Nov 10, 2026 |
| Ligand Pharmaceuticals LGND Common Stock | Through Trust | 5,025 | $286.94 | $1.4M | 4.4% | Form 4, Dec 8, 2025 |
| Orchestra BioMed Holdings OBIO Common Stock, par value $0.0001 per share | Directly | 118,118 | $7.00 | $827K | 2.5% | Form 4, May 18, 2026 |
| Lifecore Biomedical LFCR Common Stock | Directly | 69,967 | $6.37 | $446K | 1.4% | Form 4, Jun 4, 2026 |
Share counts are the amounts Jason Aryeh reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Jason Aryeh's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND Common Stock | Indirect Held by a company or fund the insider manages | 13,000 | $286.94 | $3.7M | — | Form 4, Jun 5, 2026 |
| Ligand Pharmaceuticals LGND Common Stock | Through JALAA Equities, LP Held by a company or fund the insider manages | 8,000 | $286.94 | $2.3M | — | Form 4, Nov 10, 2026 |
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Sold | LGND | 500 | $319.99 | $160K | View |
| Nov 10, 2026 | Sold | LGND | 844 | $320.00 | $270K | View |
| Nov 10, 2026 | Sold | LGND | 646 | $320.00 | $207K | View |
| Nov 10, 2026 | Sold | LGND | 10 | $320.02 | $3K | View |
| Nov 10, 2026 | Sold | LGND | 500 | $320.10 | $160K | View |
| Nov 10, 2026 | Sold | LGND | 500 | $320.20 | $160K | View |
| Nov 4, 2026 | Sold | LGND | 282 | $319.99 | $90K | View |
| Nov 2, 2026 | Sold | LGND | 700 | $320.43 | $224K | View |
| Oct 30, 2026 | Sold | LGND | 50 | $317.74 | $16K | View |
| Oct 30, 2026 | Sold | LGND | 50 | $318.23 | $16K | View |
| Oct 30, 2026 | Sold | LGND | 52 | $320.24 | $17K | View |
| Oct 30, 2026 | Sold | LGND | 1,209 | $320.42 | $387K | View |
| Oct 30, 2026 | Sold | LGND | 50 | $320.49 | $16K | View |
| Jun 11, 2026 | Sold | LGND | 4,500 | $250.00 | $1.1M | View |
| Jun 10, 2026 | Sold | LGND | 500 | $250.00 | $125K | View |
| May 18, 2026 | Bought | OBIO | 665 | $3.75 | $2K | View |
| May 15, 2026 | Bought | OBIO | 8,971 | $3.90 | $35K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 3490 | Thomas C. Dolan Director, Madison Square Garden Entertainment. New York, NY | $33.0M |
| 3491 | Paul Manning Chairman, President & CEO, Sensient Technologies. Milwaukee, WI | $33.0M |
| 3492 | Evan Bayh Director, Marathon Petroleum. Bethesda, MD | $33.0M |
| 3493 | Jason Aryeh Director, Ligand Pharmaceuticals. Palm Beach Gardens, FL | $33.0M |
| 3494 | Jeffrey Westphal Insider, Vertex. King Of Prussia, PA | $33.0M |
| 3495 | Kyle Cerminara Director, BK Technologies. Charlotte, NC | $33.0M |
| 3496 | Davis O'Connor EVP, General Counsel, Permian Resources. Denver, CO | $33.0M |
Other Ligand Pharmaceuticals insiders
All LGND insiders- John L. Higgins$120MDirector. #1162 overall
- Matthew W. Foehr$74.6MInsider. #1498 overall
- Todd C. Davis$57.2MChief Executive Officer. #1695 overall
- Matthew E. Korenberg$14.6MPresident & COO. #6393 overall
- Sunil Patel$13.3MInsider. #6658 overall
- John W. Kozarich$12.1MDirector. #7621 overall
Questions
How much stock does Jason Aryeh own?
Jason Aryeh holds $32,979,673 in listed stock based on SEC filings and current prices, mostly Ligand Pharmaceuticals (LGND). That ranks 3493rd on the Stock Rich List.
Is this Jason Aryeh's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Jason Aryeh last buy or sell stock?
The most recent open-market trade on file is a sale of 500 LGND shares on Nov 10, 2026 at $319.99.